in vitro News and Research

RSS

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

A study conducted by researchers in the United States has shown that among twenty patients with breakthrough infection following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – all of the infections were caused by variants of concerns.

26 May 2021

Researchers explore mechanical properties of cellular microenvironment in the body

Cells sense and respond to the mechanical properties of the cellular microenvironment in the body. Changes in these properties, which occur in a number of human pathologies, including cancer, can elicit abnormal responses from cells.

26 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

In a recent study by researchers in Mexico, Russia and Spain, silver nanoparticles (AgNPs) were found to inhibit SARS-CoV-2 in healthcare workers. They propose a non-pharmaceutical public health intervention consisting of mouthwash and nose rinse with an AgNPs solution to reduce morbidity among healthcare personnel exposed to the SARS-CoV-2 virus.

24 May 2021

Could saffron be an effective supplement for helping manage COVID-19?

A new study, published in the journal Cell Press, explores the potential use of saffron (Crocus sativus L.) as a drug supplement for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19).

24 May 2021

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.

24 May 2021

Computationally designed peptide blocks the entry of SARS-CoV, SARS-CoV-2, and MERS-CoV

In order to develop effective antiviral drugs, scientists design active molecules based on their structures that can prevent or disrupt the specific viral-receptor binding - this is an effective strategy to prevent the virus from entering the host.

23 May 2021

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

In Munich, Germany, scientists at Ludwig Maximilian University studied temporal adaptive immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to better understand protection against re-infection. They found functional properties of persisting memory B specific to SARS-CoV-2 may help in protect against the virus.

23 May 2021

Australian discovery could speed up SARS-CoV-2 vaccine development

To address this gap, researchers from Australia recently examined the relationship between levels of in vitro neutralization and the observed protection obtained from SARS-CoV-2 infection. They used data from 7 currently available vaccines and convalescent cohorts. Their research is published in the journal Nature Medicine.

22 May 2021

Intranasal COVID-19 therapeutic shows promise in preclinical trials

Researchers from the US and Denmark recently described a novel therapeutic option that targets the SARS-CoV-2 ribonucleic acid (RNA) using locked nucleic acid antisense oligonucleotides (LNA ASOs). They identified an LNA ASO that binds to the 5’ leader sequence of SARS-CoV-2 ORF1a/b. This disrupts a highly conserved stem-loop structure with nanomolar efficacy and inhibits viral replication in host cells.

20 May 2021

Blocking TGFβ1 could improve hematopoiesis in AML patients, indicates study

Bone marrow failure due to acute myeloid leukemia (AML) is a significant factor behind the disease's high rate of morbidity and mortality. Previous studies in mice suggest that AML cells inhibit healthy hematopoietic (blood) stem and progenitor cells (HSPC).

20 May 2021

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A team of researchers recently cross-tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies to assess their neutralization activity against different variants. The team recently released their findings as a preprint on the medRxiv* server.

20 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

FDA reminds the public about the limitations of COVID-19 antibody

The following quote is attributed to Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health.

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Researchers from the US recently assessed if severe COVID-19 is linked to procoagulant dysfunction of the endothelium and changes in the Tie2-angiopoietin axis. They assessed circulating endothelial markers in a study cohort of 98 patients with mild, moderate, or severe COVID-19. This study is published on the medRxiv* preprint server.

19 May 2021

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Researchers from Israel recently isolated a set of SARS-CoV-2 neutralizing monoclonal antibodies from blood samples of patients with severe COVID-19. They were the first to show that transgenic K18-hACE2 mice infected with lethal doses of SARS-CoV-2 can be fully protected by administering antibodies even 3 days after infection

19 May 2021

Qvella Appoints Richard Brock as VP of Global Marketing and Signals Start of Commercialization

Industry veteran departs bioMérieux to lead the commercialization of Qvella’s lineup of products starting with FAST-Prep, an automated cartridge-based system for Positive Blood Culture (PBC) processing.

19 May 2021

in vitro News and Research

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

Researchers explore mechanical properties of cellular microenvironment in the body

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

Could saffron be an effective supplement for helping manage COVID-19?

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

Computationally designed peptide blocks the entry of SARS-CoV, SARS-CoV-2, and MERS-CoV

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

Australian discovery could speed up SARS-CoV-2 vaccine development

Intranasal COVID-19 therapeutic shows promise in preclinical trials

Blocking TGFβ1 could improve hematopoiesis in AML patients, indicates study

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

FDA reminds the public about the limitations of COVID-19 antibody

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Qvella Appoints Richard Brock as VP of Global Marketing and Signals Start of Commercialization

eBook: Using iPSCs models for human disease research and drug discovery eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News